Animal models of HLA-B27-associated diseases: new outcomes.

Joint Bone Spine

Institut Cochin, Inserm U567/CNRS UMR8104/IFR116, hôpital Cochin, 27, rue du Faubourg Saint-Jacques 75014 Paris, France.

Published: March 2006

The HLA-B27 molecule is strongly associated with the spondyloarthropathies, a group of chronic inflammatory diseases, affecting the skeleton, the bowel and the skin. This association has been largely studied, but mechanisms of pathology remain unclear. The HLA-B27 transgenic rats develop a spontaneous disease that strikingly resembles human spondyloarthropathies, dependent of bacterial flora and implicating the immune system. The presence of CD4+ T cells is required, and antigen presenting cells (APC) expressing high levels of HLA-B27 likely play an important role. Indeed, APC are defective in naive T lymphocytes stimulation. This default appears to implicate the APC/T cells contact, and may result in a loss of tolerance toward microbial flora. Two models of skeletal inflammation linked to HLA-B27 have been developed in mice. The ANKENT mice develop a spontaneous ossifying enthesitis affecting ankle and tarsal joints, with increased frequency in the presence of an HLA-B27 transgene. The HLA-B27 transgenic mice lacking endogenous beta2 microglobulin develop arthritis of hind-paws. In this model, homodimers of B27 heavy chains could be implicated in the pathogenesis by presenting exogenous peptides to CD4+ T cells.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2005.03.016DOI Listing

Publication Analysis

Top Keywords

hla-b27 transgenic
8
develop spontaneous
8
cd4+ cells
8
hla-b27
6
animal models
4
models hla-b27-associated
4
hla-b27-associated diseases
4
diseases outcomes
4
outcomes hla-b27
4
hla-b27 molecule
4

Similar Publications

Introduction: Inflammatory bowel diseases (IBDs) are chronic immune driven intestinal disorders with marked metabolic alteration. Mass spectrometry imaging (MSI) enables the direct visualization of biomolecules within tissues and facilitates the study of metabolic changes. Integrating multiple spatial information sources is a promising approach for discovering new biomarkers and understanding biochemical alteration within the context of the disease.

View Article and Find Full Text PDF

serovar Typhimurium (STm) causes gastroenteritis and can progress to reactive arthritis (ReA). STm forms biofilms in the gut that secrete the amyloid curli, which we previously demonstrated can trigger autoimmunity in mice. HLA-B27 is a genetic risk factor for ReA; activation of the unfolded protein response (UPR) due to HLA-B27 misfolding is thought to play a critical role in ReA pathogenesis.

View Article and Find Full Text PDF
Article Synopsis
  • HLA-B27's association with spondyloarthritis (SpA) has been studied for 50 years, revealing its impact on the bone morphogenetic protein (BMP) pathway in Drosophila, which leads to a specific phenotype.
  • Researchers investigated the genetic interactions between the TGFβ pathway and HLA-B27 in transgenic Drosophila and identified key interactions in T cells from HLA-B27/hβ2m rats.
  • The study found that both the TGFβ and BMP pathways are deregulated in the context of HLA-B27, leading to increased phosphorylation of SMAD proteins and changes in gene expression related to immune responses.
View Article and Find Full Text PDF
Article Synopsis
  • HLA-B27, a significant risk factor for spondyloarthritis (SpA), may involve impaired protein folding and subsequent inflammation pathways, particularly IL-23 induced by endoplasmic reticulum (ER) stress.
  • Researchers studied the effect of deleting the CHOP transcription factor, which influences ER stress-related IL-23 production, on gut inflammation in genetically modified rats (HLA-B27-Tg).
  • Findings revealed that removing CHOP did not reduce gut inflammation; instead, it increased other pro-inflammatory markers, suggesting that CHOP might actually help mitigate severe gut inflammation linked to HLA-B27.
View Article and Find Full Text PDF

The therapeutic management of Crohn's disease (CD), a chronic relapsing-remitting inflammatory bowel disease (IBD), is highly challenging. Surgical resection is sometimes a necessary procedure even though it is often associated with postoperative recurrences (PORs). Tofacitinib, an orally active small molecule Janus kinase inhibitor, is an anti-inflammatory drug meant to limit PORs in CD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!